Is Lancet Oncology a Good Journal? Impact Factor, Scope, and Fit Guide
Lancet Oncology (IF 35.9) publishes practice-changing cancer research with a global perspective. 75% desk rejection rate. How it compares to JCO, Annals of Oncology, and JAMA Oncology.
Journal fit
See whether this paper looks realistic for The Lancet Oncology.
Run the Free Readiness Scan with The Lancet Oncology as your target journal and see whether this paper looks like a realistic submission.
The Lancet Oncology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 35.9 puts The Lancet Oncology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~8% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: The Lancet Oncology takes ~14 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read The Lancet Oncology as a target
This page should help you decide whether The Lancet Oncology belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | The Lancet Oncology publishes cancer research that changes practice globally. Part of the Lancet family, it. |
Editors prioritize | Practice-changing clinical impact |
Think twice if | Submitting Phase 2 trials as practice-changing |
Typical article types | Article, Fast-Track Article, Review |
Lancet Oncology is one of the top oncology journals in the world, with a 2024 impact factor of 35.9. Part of The Lancet family, it publishes practice-changing cancer research with an emphasis on international enrollment, global health oncology, and cancer care equity. Roughly 75% of submissions are desk-rejected, making it one of the most selective venues in oncology publishing.
The journal's editorial identity is distinct from its competitors. While JCO is the ASCO journal and naturally centers on US clinical practice, and Annals of Oncology is the ESMO journal with European focus, Lancet Oncology specifically seeks cancer research with a global perspective. Multinational trials, studies from low- and middle-income countries, and papers that address cancer care equity get a more favorable editorial read here than at any other top oncology journal.
Lancet Oncology at a glance
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 35.9 |
CiteScore (2024) | 65.8 |
Publisher | Elsevier (The Lancet) |
Model | Subscription (OA option available) |
Acceptance rate | ~8-10% overall; ~75% desk rejection |
First decision | 1-2 weeks for desk rejections; 6-10 weeks for reviewed papers |
Quartile | Q1 Oncology |
Scope | Practice-changing clinical oncology with global and international perspectives |
The editorial distinction: global perspective, not just global enrollment
Lancet Oncology's editors look for three things on the first page: (1) a clinical question that matters to oncologists internationally, (2) evidence strong enough to change practice or guidelines, and (3) a framing that acknowledges the global cancer landscape rather than treating one country's healthcare system as the default.
This third criterion is what separates Lancet Oncology from JCO and JAMA Oncology. A large randomized trial that would change NCCN guidelines is a JCO paper. The same trial, conducted across multiple continents with explicit consideration of how the findings apply in different healthcare systems, is a Lancet Oncology paper. The global framing is not a marketing addition. It is the journal's editorial identity.
The 75% desk rejection rate means the editorial screen is harsh. In-house editors with medical and oncology expertise review every submission. Biology-first papers, early-phase trials, single-center studies, and disease-site papers without broad oncology relevance are rejected before peer review.
How Lancet Oncology compares to realistic alternatives
Feature | Lancet Oncology | JCO | Annals of Oncology | JAMA Oncology |
|---|---|---|---|---|
IF (2024) | 35.9 | 41.9 | 65.4 | 22.5 |
Acceptance rate | ~8-10% | ~10-12% | ~10-15% | ~8-10% |
Cost | Subscription (OA option ~$5,000) | Subscription | ~$5,700 (OA option) | Subscription |
Best for | Global oncology, international trials | US clinical practice (ASCO) | European oncology, ESMO guidelines | Broad oncology care (JAMA Network) |
Desk rejection | ~75% | ~50-60% | ~50% | ~70% |
Selectivity signal | Very strong | Very strong | Exceptional | Very strong |
Four comparisons that matter:
Lancet Oncology vs. JCO: JCO (IF 41.9, ASCO) has the highest IF among dedicated oncology journals and dominates US clinical practice. If the trial is primarily relevant to US or NCCN-guided practice, JCO is the natural home. If the trial has multinational enrollment and global health implications, Lancet Oncology may be the better fit. For many papers, either journal would work, and the decision comes down to which editorial perspective matches the paper's framing.
Lancet Oncology vs. Annals of Oncology: Annals of Oncology (IF 65.4, ESMO) has a substantially higher IF and publishes the papers that change ESMO guidelines. It is the strongest oncology journal by IF. Lancet Oncology is more accessible (lower IF, slightly higher acceptance rate) and places more weight on global health perspectives. If the paper is a landmark European trial, Annals of Oncology is the target. If it is a multinational trial with global reach, Lancet Oncology competes well.
Lancet Oncology vs. JAMA Oncology: JAMA Oncology (IF 20.1) publishes across all of oncology and benefits from the JAMA Network's broad readership. It is less selective than Lancet Oncology by IF but similarly harsh on desk rejections. If the paper is strong clinical oncology without a specific global framing, JAMA Oncology may be the cleaner submission.
Lancet Oncology vs. Cancer Discovery/Nature Cancer: For biology-first oncology research (genomics, mechanisms, preclinical work), Cancer Discovery (IF 33.3) and Nature Cancer (IF 28.5) are stronger fits. Lancet Oncology is a clinical journal. Translational work without clinical endpoints rarely survives its editorial screen.
Submit if
- The paper reports a clinical trial or large cohort study that could change oncology treatment guidelines
- The enrollment is multinational or the findings explicitly address how they apply across healthcare systems
- The cancer type and intervention are relevant to a broad oncology audience, not just one disease-site community
- The "Research in Context" summary can be written in two sentences without stretching
- The paper has a global health, equity, or access dimension that strengthens the clinical message
Journal fit
See whether this paper looks realistic for The Lancet Oncology.
Run the scan with The Lancet Oncology as the target. Get a manuscript-specific fit signal before you commit.
Think twice if
- The paper is biology-first without clinical endpoints or direct practice implications
- The study is a single-center, early-phase trial without practice-changing implications
- The real audience is one disease-site community rather than broad oncology
- The global framing is wording added to the introduction rather than embedded in the study design
- JCO, JAMA Oncology, or a subspecialty journal (e.g., Journal of Thoracic Oncology, Breast Cancer Research) would more honestly match the paper's scope
What strong Lancet Oncology papers share
- Practice consequence stated in the first sentence: the abstract tells the reader what should change in cancer care based on these results
- International or global design: enrollment spans multiple countries, or the analysis explicitly addresses applicability across healthcare settings
- Adequate trial size: phase 3 RCTs, large meta-analyses, and population-level cohort studies dominate the journal's pages
- Equity or access awareness: the strongest papers acknowledge disparities in cancer care access and discuss implications for underserved populations
- Clean, guideline-ready conclusions: the discussion ends with what oncologists should do differently, not with what future research might show
Frequently asked questions
What is the Lancet Oncology impact factor?
The 2024 JCR impact factor is 35.9. Lancet Oncology ranks among the top oncology journals alongside JCO (IF 41.9) and Annals of Oncology (IF 65.4). It is part of The Lancet family and specifically emphasizes practice-changing oncology with international and global health perspectives.
What is the Lancet Oncology acceptance rate?
Overall acceptance is approximately 8-10%, but the effective bar is higher because roughly 75% of submissions are desk-rejected before peer review. Papers that survive the editorial screen typically report large-scale clinical trials, global health oncology data, or results that would directly change treatment guidelines.
How does Lancet Oncology compare to JCO?
JCO (IF 41.9, ASCO) has a higher IF and stronger US clinical oncology influence. Lancet Oncology (IF 35.9) emphasizes international oncology, global health perspectives, and cancer care equity. JCO is stronger for US practice-focused trials. Lancet Oncology is stronger for trials with international enrollment or global health framing. Both are top-tier, and the best choice depends on geographic scope and audience.
What is Lancet Oncology's desk rejection rate?
Approximately 75% of submissions are desk-rejected, typically within 1-2 weeks. The in-house editors screen for immediate practice consequence, adequate trial size, and international relevance. Papers that are biology-first, single-center, or early-phase without practice-changing implications are rejected before peer review.
Bottom line
Lancet Oncology is one of the three most important oncology journals, alongside JCO and Annals of Oncology. Its IF of 35.9 and extremely high desk rejection rate reflect a journal that publishes only practice-changing cancer research with genuine international relevance. The fit test: would this paper change how oncologists treat cancer across multiple healthcare systems, and can you state that in two sentences?
If you are unsure whether the practice-changing argument is strong enough, a Lancet Oncology practice-change threshold and global framing check can evaluate the paper's clinical evidence and global framing and suggest whether Lancet Oncology, JCO, or another venue is the right target.
Frequently asked questions
The 2024 JCR impact factor is 35.9. Lancet Oncology ranks among the top oncology journals alongside JCO (IF 41.9) and Annals of Oncology (IF 65.4). It is part of The Lancet family and specifically emphasizes practice-changing oncology with international and global health perspectives.
Overall acceptance is approximately 8-10%, but the effective bar is higher because roughly 75% of submissions are desk-rejected before peer review. Papers that survive the editorial screen typically report large-scale clinical trials, global health oncology data, or results that would directly change treatment guidelines.
JCO (IF 41.9, ASCO) has a higher IF and stronger US clinical oncology influence. Lancet Oncology (IF 35.9) emphasizes international oncology, global health perspectives, and cancer care equity. JCO is stronger for US practice-focused trials. Lancet Oncology is stronger for trials with international enrollment or global health framing. Both are top-tier, and the best choice depends on geographic scope and audience.
Approximately 75% of submissions are desk-rejected, typically within 1-2 weeks. The in-house editors screen for immediate practice consequence, adequate trial size, and international relevance. Papers that are biology-first, single-center, or early-phase without practice-changing implications are rejected before peer review.
Sources
- 1. The Lancet Oncology journal page, Elsevier.
- 2. The Lancet Oncology information for authors, Elsevier.
- 3. Clarivate Journal Citation Reports (released June 2025).
Final step
See whether this paper fits The Lancet Oncology.
Run the Free Readiness Scan with The Lancet Oncology as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- How to Submit to Lancet Oncology: Complete Guide
- How to Avoid Desk Rejection at Lancet Oncology
- Lancet Oncology Review Time: What to Expect From Submission to Decision
- Lancet Oncology Acceptance Rate 2026: How Selective Is It?
- Lancet Oncology Impact Factor 2026: 35.9 - The Top Clinical Oncology Journal
- European Heart Journal vs Lancet Oncology: Which Journal Should You Choose?
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits The Lancet Oncology.
Anthropic Privacy Partner. Zero-retention manuscript processing.